ARTICLE | Clinical News

After Phase III results, AZ's COPD combo heading for submissions

January 26, 2018 9:36 PM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) said triple combination therapy PT010 met six of seven primary endpoints evaluating lung function in the Phase III KRONOS trial to treat moderate to very severe chronic obstructive pulmonary disease. The company plans to submit regulatory applications for the combo next half in Japan and China, and next year in the U.S. and Europe.

PT010 combines glycopyrrolate (PT001), a long-acting muscarinic antagonist (LAMA); formoterol fumarate (PT005), a long-acting beta-2 agonist (LABA); and an inhaled corticosteroid (ICS), and is delivered via a single metered-dose hydrofluoroalkane (HFA) inhaler...